STUDresearch · Peptide
Mod GRF 1-29
Also known as
CJC-1295 without DAC · CJC-1295 no DAC · Modified GRF 1-29 · Mod GRF · Mod GRF (1-29) · CJC no DAC · tetra-substituted GRF 1-29 · tetrasubstituted GRF (1-29) · CJC-1295 (no DAC) · CJC-1295 No-DAC · modGRF
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Systemic
SubQ
Growth hormone axis
Systemic — short-acting GHRH analog; whole-body GH pulses via pituitary GHRH receptors, not local tissue repair.
What people say
Mod GRF 1-29 is a four-substitution, short-acting GHRH analog often sold as CJC-1295 no DAC. It is not the albumin-binding DAC-CJC product, and data from native GHRH or a one-substitution analog are only comparators.
Doses people talk about
These are descriptive blend reports, not a progression. Combined mass remains combined unless the label ratio is stated; no amount is inferred from reconstitution volume or another user's product.
How it may feel
Blend experiences conflict. One thread began at 100 mcg of each nightly with no acute, sleep or water change, then its same account posted inconsistent 150/150 and 300/300 updates, possible slight sleep improvement, and warmth/flushing around ten minutes after one claimed 300/300 exposure. Third-person 'subject' wording, an explicit GPT reference and partner peptides limit authorship and Mod GRF-only attribution.
Six-week thread starting exposure100 mcg Mod GRF + 100 mcg Ipamorelin
The thread began with this once-nightly exposure for six weeks, an IGF-1 change from 121 to 134, and no reported acute, sleep or water effect.
Same-account 150/150 update150 mcg Mod GRF + 150 mcg Ipamorelin
The same account later said this exposure still produced little difference and that sleep may have improved slightly; without wearable data, the post treated that change as uncertain.
Contradictory same-account 300/300 statements300 mcg Mod GRF + 300 mcg Ipamorelin
One comment said exposure had already increased to 300/300 with light facial warmth/flushing around ten minutes later; another said the account would try 300/300. The conflict is unresolved, so no final dose is inferred.
Twice-daily log100 mcg Mod GRF + 100 mcg GHRP-2
Each component was reported per injection, twice daily; reconstitution volumes in the source are not reproduced or used to infer mass.
Higher mixed-report exposure200 mcg Mod GRF + 300 mcg Ipamorelin
One author associated months at this per-component exposure with water retention and sleepiness, later reduced to 100 mcg of each, and changed diet near later benefit claims.
Premixed-vial discussion500 mcg combined blend
For a product stated as 6 mg Mod GRF / 15 mg Ipamorelin, a commenter calculated roughly 143 mcg + 357 mcg by label ratio. That arithmetic applies only to that stated blend label, not reconstitution volume or other products.
Half-life & effect duration
- Half-life in the body
- Exact no-DAC peptide · common community estimateAbout 25–30 minutes
- Other community guidesAbout 1–2 hours
- Felt duration people report
- Combination reportsNo acute or sleep change, slight sleep improvement, water retention or sleepiness
- Flushing accountLight facial warmth around 10 minutes after a changed combination
Cycles people discuss
Community stacks commonly run 8–12 weeks, with shorter 4–6 week probes and varying weekly breaks. These are informal blend practices, not exact-product dose-finding or safety standards.
Timing
Bedtime is the most common pulse; some multi-daily routines add morning-fasted or post-workout use and separate doses from meals. Five-on/two-off and continuous-week patterns both appear, with no clear evidence winner.
Stacks
Most inspected experiences combined Mod GRF with Ipamorelin or GHRP-2. Effects, adverse symptoms and laboratory changes from a blend cannot be assigned to Mod GRF alone.
Watch for
Long-term data gap: Controlled multi-year athletic and safety outcome data for Mod GRF + GHRP stacks essentially do not exist.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A human parent-plasma half-life for exact four-substitution Mod GRF 1-29 was not established in the reviewed sources.
A primary study in 10 healthy men measured 6.7 ± 0.5 minutes for D-Ala2 GHRH(1-29) and 4.3 ± 1.4 minutes for native GHRH by constant IV infusion. Separate DAC-CJC research reports 5.8–8.1 days after SubQ dosing.
The D-Ala2 analog has one substitution, not four, and used constant IV infusion. DAC-CJC carries an albumin-binding conjugate. Neither value can be assigned to SubQ Mod GRF no DAC.
- Soule et al. — Pharmacokinetics and pharmacodynamics of D-Ala2-GHRH(1-29) in normal men (opens in a new tab)Ten healthy men received constant IV infusion at 25 ng/kg/min; reported half-lives were 6.7 ± 0.5 minutes for D-Ala2 GHRH(1-29) and 4.3 ± 1.4 minutes for native GHRH(1-29).One-substitution analog under constant IV infusion, not the four-substitution Mod GRF sequence, SubQ community route or a blend product.
- Teichman et al. — Prolonged stimulation of growth hormone and IGF-I by CJC-1295 (opens in a new tab)Healthy adults received single or repeated SubQ CJC-1295 with DAC; reported estimated half-life was 5.8–8.1 days with multi-day GH and IGF-I changes.DAC albumin-binding conjugate, not no-DAC Mod GRF; its half-life and dosing logic cannot be transferred to the short peptide.
Felt duration people report
Inspected blend reports do not establish a consistent felt-onset or persistence window for Mod GRF itself.
One thread began at 100 mcg per component nightly for six weeks with no acute, sleep or water effect. Its same account later said 150/150 produced little difference with possible slight sleep improvement, and inconsistently described 300/300 as both a future plan and an already-made increase followed by light facial warmth/flushing around ten minutes. A separate author reported water/sleepiness at 200 + 300 mcg and later claimed sleep/recovery change after reducing amounts and changing diet.
All key reports combined Mod GRF with a GHRP. In the six-week thread, moderator-required third-person 'subject' language, an explicit same-account GPT reference and internally inconsistent dose updates prevent treating authorship or sequence as verified. Product identities were unverified, and effects cannot be assigned to Mod GRF or timed causally.
- Reddit r/Peptidesource — CJC-1295 no DAC + Ipamorelin for six weeks (opens in a new tab)Thread began with moderator-compliant third-person 'subject' wording: 100 mcg Mod GRF + 100 mcg Ipamorelin once nightly for six weeks, IGF-1 121 to 134, and no acute, sleep or water effects. Same-account comments later said 150/150 made little difference with possible slight sleep improvement; elsewhere, they both claimed an increase to 300/300 with light facial warmth/flushing around ten minutes and said they would try 300/300.Anonymous uncontrolled blend discussion with unverified product and laboratory conditions. Moderator-required third-person 'subject' wording and an explicit same-account GPT reference make personal authorship uncertain; same-account 150/150 and 300/300 updates are internally inconsistent. Cannot isolate either component or establish chronology, response prevalence or causation.
- Reddit r/Peptides — GHRP-2 and Mod GRF log (opens in a new tab)Author reported 100 mcg GHRP-2 + 100 mcg Mod GRF per injection twice daily, later summarizing 0.2 mg/day of each. Separate shoulder improvement followed TB-500 and stretching and is not attributed to Mod GRF.Anonymous uncontrolled combination log; includes preparation details intentionally not reproduced, and later interventions confound recovery outcomes.
- Reddit r/Peptides — CJC no DAC + Ipamorelin experiences (opens in a new tab)One author described 200 mcg Mod GRF + 300 mcg Ipamorelin with water retention/sleepiness over months, later 100 mcg each and a shift from no effect to claimed sleep/recovery improvement after dietary change; another user claimed 100/100 three times daily.Anonymous changing same-author exposure and diet, unverified blend identity, long recall and no comparator; cannot establish component efficacy, dose response or timing.
Other context in this card
- Reddit r/Peptides — CJC/Ipamorelin blend dose discussion (opens in a new tab)For a vial stated as 6 mg CJC no DAC / 15 mg Ipamorelin, the original poster discussed 500 mcg combined mass and a commenter calculated about 143 mcg + 357 mcg from that stated label ratio.Anonymous calculation based on an unverified product label. It applies only to the stated blend ratio and is not inferred from reconstitution volume or transferable to other vials.
What people say
- Sleep reports conflict: One six-week 100 mcg + 100 mcg nightly account reported no acute effect or sleep change, while another same-author thread moved from 'nothing' to claimed sleep/recovery improvement after about three weeks alongside diet change. These are blend reports, not Mod GRF-only effects. forum
- Recovery: Easier next-day readiness and less soreness after several weeks — heavily confounded by sleep, training volume, and co-stacks. forum
- Recomp assist: Gradual lean-mass support and softer fat-loss edge over months, not week-one drama or a rapid cut drug. forum
- Vs DAC preference: Users who want sharp GH peaks that clear (troughs between pulses) over multi-day GH/IGF-1 elevation favor no-DAC + frequent GHRP pins. forum
- GHRH + GHRP synergy: Dominant thesis — pulse amplitude claimed larger when Mod GRF is co-timed with Ipamorelin (or older GHRP-2/6/hexarelin) than either alone; some vendor write-ups recycle “multi-fold” synergy language without a clean modern head-to-head RCT. forum
- Vs sermorelin: Often cast as more practical/potent per pulse because of DPP-IV resistance and ~30 min half-life vs unmodified GRF 1–29’s minutes-scale clearance; sermorelin keeps more clinic/compounding branding. forum
- Fullness / skin: Mild GH-like fullness or skin-quality notes; early water can fake a “full” look. anecdote
- Labs as check, not win: Some track serum IGF-1 as an “axis engaged” surrogate; no-DAC trough IGF-1 moves are usually milder and harder to read than weekly DAC — a flat IGF-1 does not prove the pulse never happened. forum
- Vs exogenous GH: Framed as “stimulate your own GH” with pituitary feedback still in play — forum outcomes still far below high-dose somatropin claims. forum
- DAC clinical contrast (not Mod GRF data): Teichman 2006 (DAC form) — single subq doses raised mean GH ~2- to 10-fold for ≥6 days and IGF-I ~1.5- to 3-fold for ~9–11 days. That is evidence for long-acting CJC, not proof of Mod GRF recomp claims. trial
Doses people talk about
- Per-shot modal band: ~100–200 mcg subcutaneous is the most repeated standard per administration. forum
- Wider per-shot talk: ~50–300 mcg per pulse appears across guides; 100 mcg and 200 mcg dominate “start” and “standard” charts. forum
- Saturation lore: Community and vendor notes claim GHRH-receptor occupancy flattens roughly around ~100 mcg per pulse, with little proportional GH gain past ~150 mcg — used to argue against mega-dosing solo Mod GRF. This is receptor-curve folklore, not a universal human titration study. forum
- Frequency: 1–3× daily because of short half-life; beginners often start once nightly; aggressive recomp logs add AM fasted and/or post-workout. forum
- Inspected Mod GRF + Ipamorelin reports and broader dual talk: Accounts included 100 mcg of each nightly for six weeks, 100 mcg of each twice daily, and 200 mcg Mod GRF + 300 mcg Ipamorelin before a later reduction. Broader legacy variants include ~100/200, ~200/200, and ~100–200 Mod GRF + ~100–300 mcg Ipamorelin per session. forum
- Ipa-heavy variants: Some logs run Ipa ~150–300 mcg with Mod GRF fixed ~100–200 mcg when sides allow — ratio debates are common and not standardized. forum
- Beginner-style charts (vendor/community): Solo ~100 mcg 1–2× daily for first exposure; or dual ~100/100 once nightly before adding second pulse. forum
- Standard dual charts: ~100 mcg each, 2–3× daily, 8–16 week blocks in many “recomp” tables. forum
- Aggressive dual charts: ~100 mcg Mod GRF + ~200 mcg Ipa, 3× daily — more pins, more cost, more side risk talk. forum
- Fat-loss timing emphasis: AM fasted + bedtime dual pulses framed for lipolysis/sleep windows more than a third mid-day pin. forum
- Food timing (critical in bro culture): Empty stomach — commonly ≥90 minutes after a meal (some say ~2 h post-meal, especially after carbs/fats), then wait ~20–60+ minutes before eating again. Insulin/glucose near meals are said to blunt the GH pulse substantially (community cites large % blunting from carb-containing meals). forum
- Bedtime priority: Pre-sleep dose aimed at the large natural nocturnal GH surge is the single most common timing rule even when multi-daily is used. forum
- 5-on / 2-off: Pin weekdays, skip weekends — cost, compliance, and theoretical desensitization reduction; necessity vs daily continuous is debated and not proven head-to-head. forum
- 7-day continuous: Also common in “steady protocol” write-ups; no clear evidence winner vs 5/2. forum
- Not DAC math: Do not convert weekly DAC milligrams into daily no-DAC micrograms (or reverse). Half-lives and GH patterns differ by orders of magnitude (~minutes vs ~days). forum
- Uncertainty: Purity, DAC vs no-DAC mislabel, underdosed vials, and blend-ratio chaos are structural gray-market risks without independent testing. forum
- Premixed blend vials: Commerce often sells 5 mg/5 mg or 10 mg/10 mg CJC no-DAC + Ipamorelin 1:1; total blend per pin often ~200–400 mcg combined (e.g. 100+100 or 200+200). Vendor ratios and labeling (total peptide vs per-peptide) vary — map the label. forum
- Framing: Ranges below are research-chem, clinic-marketing, and forum discussion — not prescriptions, not medical advice, not safety-validated athletic protocols. forum
How it may feel
- Minutes after shot: Some get brief facial/chest flush or warmth within ~5–30 minutes that fades within ~10–60 minutes; many feel nothing acute. forum
- Nights 1–7: Little daytime feel; bedtime users may note sleep depth or dream intensity change same week if empty-stomach timing is solid. forum
- Weeks 1–2: Sleep and morning recovery are the first “sticks if anything will” signals; physique usually unchanged. forum
- Weeks 3–4: More consistent sleep/recovery talk; possible mild water retention, post-shot flush, or joint stiffness as GH/IGF-1 exposure accumulates. forum
- Weeks 4–8: Community write-ups place gradual metabolic/recovery and early body-comp talk here — still highly confounded. forum
- Weeks 6–8 / 8–12: Leaner/harder-look anecdotes if any; common reassess window for cost of multi-daily pins vs results. anecdote
- Months 2–3: Bloodwork interest (IGF-1, fasting glucose) for labs-oriented users; decide continue, add pulse frequency, switch partner GHRP, or time off. forum
- After stop: Sleep/recovery edge often fades over days to a few weeks; body-comp tracks training/diet more than a rebound crash. anecdote
Cycles people discuss
- Common on-block: 8–12 weeks on for no-DAC + GHRP stacks is the most repeated community length. forum
- Longer blocks: 12–16 weeks on appears in some recomp/anti-aging-style guides before a planned break. forum
- Time off: Often ~4 weeks off after 8–12 weeks on; some use 4–8 weeks off or equal on/off folklore. Practices vary widely. forum
- Clinic-style longer runs: Some wellness pages describe multi-month nightly or multi-pulse use with periodic lab reassess (e.g. ~3 months on / ~1 month off, three cycles/year style talk for CJC/Ipa). forum
- 5-on / 2-off inside the block: Very common weekly pattern layered on top of the multi-week on/off cycle. forum
- Short probe: 4–6 weeks to test sleep response and flush/tolerance before committing multi-vial cost. forum
- Re-runs: Seasonal restarts for cuts, bulks, or camps; re-check whether product was true no-DAC if results disappoint. forum
- Desensitization debate: Forum lore argues pulsatile no-DAC + GHRP preserves receptor sensitivity better than continuous DAC “GH bleed” — mechanistic opinion, not a settled RCT. forum
- No AAS-style PCT: Not treated like steroids; no universal SERM post-cycle protocol — just time off, sleep, and training. forum
- Missed dose: Community default is skip and resume next scheduled pulse — do not double-stack into a fed window. forum
Timing
- Mod GRF estimate: ~25–30 minutes is dominant community/vendor talk, but the reviewed sources did not establish it as a human parent-plasma half-life for the exact four-substitution no-DAC peptide. forum
- Why multi-daily: Short clearance → 1–3 shots/day, each ideally co-timed with a short GHRP (Ipamorelin half-life often cited ~2 hours in community tables). forum
- Timing hierarchy: Pre-sleep empty stomach dominates; optional AM fasted and post-workout pulses for extra daily exposure. forum
- Downstream cascade: Acute GH peak is brief (hours-scale exposure talk); IGF-1 shifts and recomp stories are weeks-to-months scale. forum
- Empty-stomach rationale: Near-meal insulin/glucose (and free fatty acids in broader GH literature) are thought to blunt GHRH-stimulated GH release — the #1 “protocol fail” in community troubleshooting. forum
- Related human IV comparator, not exact Mod GRF: In 10 healthy men, constant IV infusion yielded a 6.7 ± 0.5 minute half-life for D-Ala2 GHRH(1–29) versus 4.3 ± 1.4 minutes for native GHRH(1–29). The analog had one stabilizing substitution, not Mod GRF's four. trial
- Vs DAC-CJC: DAC albumin-binding form ~5.8–8.1 days half-life in healthy adults (Teichman 2006) — weekly dosing math, not multi-daily pulse math. trial
- Pulse vs plateau framing: No-DAC = sharp GH peak then clear (natural-like troughs); DAC = multi-day elevation (bro talk: flatter “GH bleed,” though formal DAC study still saw episodic pulses). forum
- Vs class peers: Sermorelin = shorter classic fragment; Tesamorelin = stabilized GHRH with distinct clinical VAT history; DAC-CJC = long-acting opposite end of the GHRH analog spectrum. trial
More on what it is
- Naming trap: Sold almost universally as “CJC-1295 without DAC” / “CJC no DAC.” True classical CJC-1295 is the DAC (Drug Affinity Complex) albumin-binding conjugate. Mod GRF is the short-acting core peptide without that linker — not the same PK product. forum
- Why people use it: Produce sharp, short GH pulses that clear fast; almost always stacked with a GHRP (default: Ipamorelin) for bigger combined pulses, sleep, recovery, and slow recomp talk. forum
- Mechanism talk: Binds pituitary GHRH receptors on somatotrophs → endogenous GH pulse. Still needs a functioning pituitary; not exogenous rGH. Somatostatin can still blunt the pulse; GHRPs (ghrelin-receptor path) are said to lower that brake while GHRH amplifies the release. forum
- What it is: Synthetic 29-amino-acid GHRH fragment analog (GRF 1–29 backbone) with four stabilizing substitutions so it resists enzymatic breakdown better than native GRF 1–29 / sermorelin. trial
- Tetra-substitutions (positions 2, 8, 15, 27): D-Ala2 (DPP-IV resistance at N-terminus), Gln8 (reduced deamidation vs Asn), Ala15 (structural rigidity vs Gly), Leu27 (oxidation resistance vs Met). Sequence often given as Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. trial
- Half-life framing: Community/vendor sources cite ~30 minutes for Mod GRF/CJC no DAC, but the reviewed human primary study measured 6.7 minutes for a one-substitution D-Ala2 GHRH analog, not exact four-substitution Mod GRF. DAC-CJC's 5.8–8.1-day human value belongs to the albumin-binding DAC product. forum
- Evidence honesty: Human PK/IGF-1 clinical data that people cite for “CJC-1295” is overwhelmingly the DAC form (e.g. Teichman et al. 2006). No-DAC / Mod GRF bodycomp, sleep, and athletic protocols are mostly community, clinic marketing, and animal/mechanism inference — not large modern RCTs for physique endpoints. trial
- Not: Not recombinant GH, not a steroid, not CJC-1295 with DAC, not sermorelin (related but fewer substitutions / shorter practical window in bro talk), not FDA-approved for physique, sleep, or anti-aging. trial
Stacks
- + Ipamorelin (gold-standard dual): Default stack; sold as premixed blends more often than either alone; same-time empty-stomach pulses 1–3× daily. forum
- + GHRP-2: Older high-amplitude stack; more cortisol/prolactin and side talk than Ipamorelin in forum lore. forum
- + GHRP-6: Strong pulse with notable hunger — often cut-unfriendly. forum
- + Hexarelin: Discussed for strong pulses but more receptor desensitization / cortisol concern in bro science. forum
- + BPC-157 / TB-500: “Recover harder, sleep better” lifestyle stacks — heavy confounding; not a formal GH endpoint protocol. forum
- vs CJC-1295 with DAC: Weekly long-acting alternative for fewer pins and steadier IGF-1; pulse purists stay no-DAC + GHRP. Hybrid (weekly DAC + daily Ipa) exists but is philosophically messy to pulse camps. forum
- vs MK-677 (ibutamoren): Oral ghrelin-mimetic convenience comparison; more water retention, appetite, and fasting-glucose talk for many; continuous elevation vs inject pulses. forum
- vs Sermorelin: Clinic-friendly short GHRH; Mod GRF treated as “upgraded sermorelin” in forum culture for multi-pulse day stacks. forum
- vs exogenous HGH: Sometimes used as a cheaper “stimulate own GH” bridge; outcomes and sides still differ from pharmacologic rGH. forum
- Avoid double GHRH overload: Running DAC + no-DAC + sermorelin together is generally seen as redundant and side-amplifying without clear upside. forum
- Sleep hygiene co-credit: Dark room, fixed bedtime, late-carb control often co-blamed when sleep results look good. forum
- vs Tesamorelin: Visceral-fat users sometimes prefer/rotate for stronger clinical VAT framing (Egrifta lore); not 1:1 dose charts with Mod GRF. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Redness, swelling, itch, warmth — worse with same-site multi-daily pins; most common practical complaint. forum
- Flush / warmth: Transient facial or chest flush minutes after injection in a subset; usually short-lived. forum
- Headache / tingle: Brief headache or extremity paresthesias (hand/foot tingling or numbness) appear in community logs — sometimes linked to fluid shifts at higher GH-axis exposure. forum
- Water retention: Peripheral puffiness or softer look; community tables often rate no-DAC water retention as milder than DAC, but not zero — especially with aggressive multi-pulse stacks. forum
- Joint / muscle aches: Stiffness or nonspecific aches in GH-elevation context. forum
- Carpal-tunnel-like talk: Occasional hand numbness pattern classic to GH elevation literature (also noted on related agents) — dose cut or stop talk if progressive. forum
- Vivid dreams / sleep shift: Early signal for many; a minority report restless sleep instead of deeper sleep. anecdote
- Grogginess: Some bedtime dosers get morning fog; others only better sleep — split responses. anecdote
- Hunger: Milder on Mod GRF alone; more often blamed on GHRP-6 partner than on Ipamorelin or Mod GRF. forum
- Cancer / mitogenic caution: Theoretical GH/IGF-1 pathway concern with active or high-risk cancer history — standard secretagogue warning, not a Mod-GRF-specific trial endpoint. forum
- Pregnancy / unknowns: No adequate safety database for pregnancy, breastfeeding, or multi-year unmonitored wellness use. forum
- Glucose / insulin: GH can blunt insulin action — flag for metabolic risk, prediabetes, or diabetes history; fasting glucose interest on longer runs. trial
- Not FDA-approved for bodycomp: No approved indication for muscle, fat loss, sleep, or anti-aging; remains research / gray-market and compounded-clinic culture. trial
- Long-term data gap: Controlled multi-year athletic and safety outcome data for Mod GRF + GHRP stacks essentially do not exist. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.